Logo

Alnylam Reports Submission of MAA to Brazilian Health Regulatory Agency for Onpattro (patisiran) to Treat Hereditary ATTR Amyloidosis with Polyneuropathy

Share this

Alnylam Reports Submission of MAA to Brazilian Health Regulatory Agency for Onpattro (patisiran) to Treat Hereditary ATTR Amyloidosis with Polyneuropathy

Shots:

  • The MAA submission to ANVISA is based on P-III APOLLO study results assessing Onpattro in patients hATTR amyloidosis with polyneuropathy- evaluating its safety and efficacy and the results are also published in The New England Journal of Medicine in July 5- 2018
  • Alnylam’s Onpattro has also received ANIVSA’s Priority Review which is granted to innovative medicines treating rare diseases under this accelerated regulatory pathway with its expected decision in H1’20
  • Onpattro is an RNAi therapeutic that targets and silence TTR messenger RNA- further blocking the production of TTR protein before it is made targeting transthyretin (TTR)- approved in Canada- Japan and the US FDA for polyneuropathy of hATTR amyloidosis in adults and in EU and Switzerland for hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy

Click here to­ read full press release/ article | Ref: PRNewsWire | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions